Alto Neuroscience’s Depression Drug Shows Positive Biomarker Results in Phase 2 Trial

Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory Phase 2 proof-of-concept/POC trial of its drug candidate, ALTO-203. The trial enrolled 69 patients with major depressive disorder/MDD who also had elevated anhedonia, a condition characterized by a reduced ability to feel pleasure.

While the trial was not powered to show statistical significance on traditional depression scales like MADRS, it successfully identified a robust patient selection biomarker. This biomarker, the EEG high-theta/beta ratio, is a well-validated measure of abnormal cortical arousal and poor attentional control. The findings from this trial replicate results from a previous Phase 1 study in healthy volunteers, confirming that ALTO-203’s pro-cognitive and wake-promoting effects are linked to a reduction in this specific EEG ratio.

Alto Neuroscience's Depression Drug Shows Positive Biomarker Results in Phase 2 Trial

A closeup of a laboratory assistant, holding up a vial of a newly developed pharmaceutical product.

The drug is an oral histamine H3 inverse agonist and was well-tolerated in the trial, with insomnia being the most frequent adverse event. Alto Neuroscience plans to report additional results from this exploratory study at a future medical meeting and will determine the next development steps for ALTO-203 after a complete analysis of the data. The company’s goal is to use its Precision Psychiatry Platform to use objective biomarkers for targeted neuropsychiatric drug development.

Alto Neuroscience Inc. (NYSE:ANRO) is a clinical-stage biopharmaceutical company in the US.

While we acknowledge the potential of ANRO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ANRO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.